Paolo Tarantino: ATEMPT would have not been possible without the vision of Sara Tolaney

Sara Tolaney shared a post by Paolo Tarantino on X:

“Very lucky to get to work with you on this, Paolo Tarantino!!!”

Quoting Paolo Tarantino’s post on X:

“Finally, ATEMPT would have not been possible without the vision of Sara Tolaney, who designed and led the trial.

I’m incredibly grateful to have had the chance of working on ATEMPT, to have the opportunity to call Sara Tolaney mentor & friend, and to learn from her every day.”

Source: Sara Tolaney/X and Paolo Tarantino/X

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low-risk regimen is beneficial in women with early-stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines.

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.